Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

M Donadio

Showing results (51-60 of 55) with videos related to

Pageof 6
Sort By:
You have reached the last page of results.This site can display upto 55 results.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|September 6, 2007
Patients with advanced stage breast carcinoma immunoreactive to biotinylated Herceptin are most likely to benefit from trastuzumab-based therapy: an hypothesis-generating studyA Sapino, F Montemurro, C Marchiò, et al.
British Journal of Cancer|January 26, 2005
Paclitaxel, vinorelbine and 5-fluorouracil in breast cancer patients pretreated with adjuvant anthracyclinesA Berruti, R Bitossi, G Gorzegno, et al.
Tumour Biology : the Journal of the International Society for Oncodevelopmental Biology and Medicine|January 12, 2002
Independent factors predict supranormal CA 15-3 serum levels in advanced breast cancer patients at first disease relapseM Tampellini, A Berruti, G Gorzegno, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|September 17, 2018
Nine weeks versus 1 year adjuvant trastuzumab in combination with chemotherapy: final results of the phase III randomized Short-HER study‡P Conte, A Frassoldati, G Bisagni, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|June 12, 2008
Biology, prognosis and response to therapy of breast carcinomas according to HER2 scoreS Ménard, A Balsari, E Tagliabue, et al.
Pageof 6

Showing results (51-60 of 55) with videos related to

Sort By:
Pageof 6
You have reached the last page of results.This site can display upto 55 results.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|September 6, 2007
Patients with advanced stage breast carcinoma immunoreactive to biotinylated Herceptin are most likely to benefit from trastuzumab-based therapy: an hypothesis-generating studyA Sapino, F Montemurro, C Marchiò, et al.
British Journal of Cancer|January 26, 2005
Paclitaxel, vinorelbine and 5-fluorouracil in breast cancer patients pretreated with adjuvant anthracyclinesA Berruti, R Bitossi, G Gorzegno, et al.
Tumour Biology : the Journal of the International Society for Oncodevelopmental Biology and Medicine|January 12, 2002
Independent factors predict supranormal CA 15-3 serum levels in advanced breast cancer patients at first disease relapseM Tampellini, A Berruti, G Gorzegno, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|September 17, 2018
Nine weeks versus 1 year adjuvant trastuzumab in combination with chemotherapy: final results of the phase III randomized Short-HER study‡P Conte, A Frassoldati, G Bisagni, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|June 12, 2008
Biology, prognosis and response to therapy of breast carcinomas according to HER2 scoreS Ménard, A Balsari, E Tagliabue, et al.
Pageof 6